Inovio Pharmaceuticals, Inc. (INO) Dividend History
Income profile from 2017 to 2024 with payout safety and yield-on-cost trend
3-Second Income Check
Safety
Payout ratio data not available yet.
Consistency
0 straight years of dividend increases.
Income Trend
Yield on cost trend needs more history.
Dividend Scorecard
Yield & Income
Payout Safety
Growth
Total Returns
Uses precomputed total return metrics from screening data (not lot-by-lot dividend reinvestment transactions). Different time windows can produce different outcomes depending on market regime and entry point.
Income Growth Story
Dividend per share and yield on cost over time (1 years of payments)
Dividend Safety Story
EPS is the container — dividend is what's drawn out
Dividend Analysis
Payout Safety
Inovio Pharmaceuticals, Inc. has limited earnings payout data (Unknown).
Piotroski F-Score: 2/9 — weak financial health.
Growth Track Record
INO does not have a current streak of consecutive dividend increases.
Total Shareholder Returns
Beyond cash dividends, INO returns capital through share repurchases. The combined picture: 0.0% total shareholder yield.
Income Trend & Total Return
The 5-year total return is -98.7%.
DRIP Growth
A $10,000 investment made 10 years ago with dividends reinvested would have grown to approximately $276 today.
Recent Dividend Payments
Last 4 payments · Quarterly
| Ex-Date | Amount | Change | Yield % | Payment Date |
|---|---|---|---|---|
| Sep 28, 2017Latest | $0.0690 | — | 36.45% | Oct 16, 2017 |
| Aug 29, 2017 | $0.0690 | — | 28.99% | Sep 15, 2017 |
| Jul 27, 2017 | $0.0690 | — | 20.87% | Aug 15, 2017 |
| Jun 28, 2017 | $0.0690 | — | 6.99% | Jul 17, 2017 |
Dividend Peer Comparison
Peer group: Vaccines and Infectious Disease
Annual Dividend History
26 years of dividend data
| Year | DPS | YoY | Pmts | EPS | Payout | Coverage | YOC |
|---|---|---|---|---|---|---|---|
| 2024 | $0.00 | — | 0 | $-3.95 | — | — | — |
| 2023 | $0.00 | — | 0 | $-6.09 | — | — | — |
| 2022 | $0.00 | — | 0 | $-14.07 | — | — | — |
| 2021 | $0.00 | — | 0 | $-1.42 | — | — | — |
| 2020 | $0.00 | — | 0 | $-1.07 | — | — | — |
| 2019 | $0.00 | — | 0 | $-0.97 | — | — | — |
| 2018 | $0.00 | -100.0% | 0 | $-1.05 | — | — | — |
| 2017 | $0.28 | — | 4 | $-1.08 | — | — | 0.7% |
| 2016 | $0.00 | — | 0 | $-1.01 | — | — | — |
| 2015 | $0.00 | — | 0 | $-0.43 | — | — | — |
See INO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs INO Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare INO vs AGIO
See how INO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
How much dividend does INO pay per share?
Inovio Pharmaceuticals, Inc. (INO) pays a trailing 12-month dividend of N/A per share, with a current dividend yield of N/A. Payments are made Quarterly.
When is INO's next ex-dividend date?
INO's most recent ex-dividend date is N/A. You must own shares before the ex-dividend date to receive the next payment. INO typically pays dividends Quarterly.
Is INO's dividend safe?
INO's dividend safety is rated "Unknown" based on an earnings payout ratio of N/A and FCF payout ratio of N/A. The dividend history does not yet show a prolonged growth streak.
How many years has INO increased its dividend?
INO has not maintained a consecutive growth streak recently. The 5-year dividend CAGR is N/A.
How often does INO pay dividends?
Inovio Pharmaceuticals, Inc. pays dividends Quarterly. The trailing 12-month total is N/A per share. Dividend data on this page covers 7+ years from 2017 to 2024.
How much would $10,000 invested in INO grow with dividend reinvestment?
With dividends reinvested (DRIP), $10,000 invested in INO five years ago would be worth approximately $130 today. This includes both price appreciation and compounded dividend reinvestment. Use the DRIP calculator above for other time periods.
What is INO's yield on cost for long-term holders?
INO's yield on cost — the current dividend divided by the original purchase price — is N/A for a 5-year holding period. This means long-term holders earn a higher effective yield than today's N/A market yield, thanks to the lower original cost basis.